Charles W Murry

20060040389, Feb 23, 2006

Aug 17, 2004

10/920795

Charles Murry - Seattle WA, US
Michael Laflamme - Seattle WA, US

C12N 5/08
G01N 33/567

435377000, 435366000, 435007200

Viable differentiating cells from in vitro cultures of stem cells are selected for by partial dissociation to provide cell aggregates. Aggregates comprising cells of interest are selected for phenotypic features using methods that substantially maintain the cell to cell contacts in the aggregate.

20070166288, Jul 19, 2007

Jan 19, 2006

11/336502

Charles Murry - Seattle WA, US
Michael Laflamme - Seattle WA, US

A61K 35/12
C12N 5/08

424093700, 435366000

The survival of cells during transplantation is enhanced. Cells to be transplanted are administered in a formulation that provides two ore more survival enhancing factors. Optionally, prior to administration, the cells are cultured in the presence of factors that enhance survival, and may be heat shocked prior to transplantation.

20220296572, Sep 22, 2022

Mar 2, 2022

17/685180

- Seattle WA, US
Charles E. MURRY - Seattle WA, US

Sana Biotechnology, Inc. - Seattle WA

A61K 31/436
A61K 35/34
A61K 31/343
A61P 37/06

Provided are methods and uses related to cardiomyocyte cell therapies involving the administration of immunosuppressive agents for reducing or preventing rejection of administered allogeneic cardiomyocytes. In some embodiments, the methods are for treating a subject with a heart disease or condition in combination with a cardiomyocyte cell therapy.

20230077983, Mar 16, 2023

Feb 9, 2021

17/798127

- Seattle WA, US
- Nashvillel TN, US
Kenta NAKAMURA - Seattle WA, US
Charles E. MURRY - Seattle WA, US
Bjorn KNOLLMANN - Nashville TN, US

UNIVERSITY OF WASHINGTON - Seattle WA
VANDERBILT UNIVERSITY - Nashville TN

A61K 31/343
A61K 31/55
C12N 5/077
A61K 35/34
A61K 9/00
A61P 9/00

Described herein are methods and compositions related to treating and preventing an engraftment arrhythmia with an effective amount of amiodarone and ivabradine. Also described herein is a method of cardiomyocyte transplant, the method comprises: dministering in vitro-differentiated cardiomyocytes to cardiac tissue of a subject in need thereof; and administering to the subject an amount of amiodarone and an amount of ivabradine effective to reduce engraftment arrhythmia in the subject.

20200000886, Jan 2, 2020

Jun 28, 2019

16/457441

- Seattle WA, US
Charles E. MURRY - Seattle WA, US
Xuan GUAN - Seattle WA, US

UNIVERSITY OF WASHINGTON - Seattle WA

A61K 38/44
C12N 15/86
C12N 15/52
A61K 48/00

Provided herein are isolated nucleic acids that encode a stable form of Rrm2 for the use of increasing the intracellular Rrm2 protein levels and cytosolic 2-deoxy-ATP (dATP) levels. Further provided herein are methods for treating a cardiac disease or disorder, e.g., myocardial infarction or myocardial ischemia, by administering the isolated nucleic acids, a polypeptide encoded by the isolated nucleic acids, or composition comprising the isolated nucleic acids to a subject in need thereof.

20190029549, Jan 31, 2019

Mar 10, 2017

16/082847

- Seattle WA, US
Shiv Bhandari - Seattle WA, US
Kevin S. Bielawski - Seattle WA, US
Andrea B. Leonard - Seattle WA, US
Charles E. Murry - Seattle WA, US

A61B 5/04
A61B 5/00

Devices and techniques for magnetic detection of myocardial forces are generally described. In some examples, cardiac tissue may be cultured such that the cardiac tissue adheres to a first post and a second post. In further examples, a magnetometer may detect a change in a magnetic field resulting from a deflection of the first post in a first direction from a first position to a second position. In some other examples a signal corresponding to the change in the magnetic field may be generated. In still other examples, frequencies of the signal outside of a first frequency range may be excluded to produce a filtered signal. In various examples, the first frequency range may include frequencies associated with beating of cardiac tissue. In still further examples, a force exerted by the cardiac tissue may be determined based at least in part on the filtered signal.

20160186139, Jun 30, 2016

May 29, 2012

14/122226

- Seattle WA, US
Michael Laflamme - Seattle WA, US
Charles Murry - Seattle WA, US
F. Steven Korte - Port Orchard WA, US
Scott Lundy - Schoreline WA, US
Stephen Denison Hauschka - Seattle WA, US
Jeffrey S. Chamberlain - Seattle WA, US

University of Washington - Seattle WA

C12N 5/077
C12N 9/02
A61K 48/00
A61K 35/34
A61K 9/00
C12N 15/86
C12N 7/00

Compositions and methods for improving cardiac function, myocardial contractility and relaxation in a mammal are provided. Cardiomyocytes transfected with one or more expression vectors comprising a ribonucleotide reductase subunit R1-encoding nucleic acid sequence and a ribonucleotide reductase subunit R2-encoding nucleic acid sequence operably linked to a promoter are grafted to a mammalian myocardium. Also provided are compositions and methods for delivering dATP to a myocardium through grafting of donor cells overexpressing R1 and R2. dATP is thereby produced in situ and delivered through gap junctions established between donor cells and host cardiomyocytes. Alternatively, viral vector(s) having the R1 and R2-encoding construct(s) are administered to the mammal directly. Improvement of cardiac function can also be effected by administration of vectors comprising a nucleic acid sequence encoding a L48Q, 61 Q, or L57Q cTnC variant.

20150125952, May 7, 2015

Mar 15, 2013

14/390490

- Seattle WA, US
Michael Laflamme - Seattle WA, US
Charles Murry - Seattle WA, US
Kshitiz Gupta - Seattle WA, US
Hyok Yoo - Shoreline WA, US
Alex Jiao - Seattle WA, US

C12N 5/0735
C12N 5/074
C12N 5/077

435366, 435396

The present invention generally relates to the field of cell growth and tissue engineering, in particular, tissue engineered compositions comprising a nanotextured substrate which is structurally configured for growth of cells in an anatomically correct adult phenotype in vitro. In particular, described herein are nanotextured substrates which are structurally configured for the anisotropic organization, maturation, and growth of in vitro-differentiated muscle cells, such as cardiomyocytes, and methods for the production and use thereof in varying sizes, nanotextures and substrate rigidities. In vitro-differentiated cardiomyocytes grown on the nanotextured substrates described herein are better-differentiated and more closely mimic adult cardiac tissue than the same cells grown on a non-textured substrate of the same composition. The nanotextured substrate/cell constructs provide a platform for screening to predict the effect of test agents or drugs on, for example, human cardiac tissue, including patient-derived tissue, or for the identification of agents that effect various cardiac functional parameters.